Form 4: Hologic Director Christiana Stamoulis Reports Acquisition of Stock and Stock Options

Director Christiana Stamoulis reports acquisition of restricted stock units and stock options in Hologic Inc.

Summary

• On February 26, 2025, Christiana Stamoulis, a director of Hologic Inc. (HOLX), acquired 1,864 shares of common stock.
• These shares were obtained through restricted stock units that vest on the date of the 2026 Annual Meeting of Stockholders.
• Stamoulis also acquired 5,535 non-qualified stock options with an exercise price of $64.36, which become exercisable on the date of the 2026 Annual Meeting of Stockholders and expire on February 26, 2035.
• Following these transactions, Stamoulis beneficially owns 47,336 shares of Hologic common stock and 5,535 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option acquisitions by a director, which generally reflects confidence but doesn't provide strong positive or negative signals.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting and exercisability of the acquired securities are tied to the 2026 Annual Meeting of Stockholders, suggesting a long-term perspective.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing indicates a director's continued investment in Hologic.

Comparison to Industry Standards

• Comparing Christiana Stamoulis's holdings to those of other directors in similar medical technology companies would provide a benchmark for assessing the magnitude of her investment.
• Analyzing the vesting schedules of restricted stock units and the terms of stock options against industry norms would offer insights into the competitiveness of Hologic's executive compensation packages.
• Comparing Hologic's insider transaction activity to that of companies like Abbott Laboratories (ABT) or Medtronic (MDT) could reveal broader trends in executive sentiment within the medical device sector.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder sentiment.
• The vesting and exercisability of the securities tied to the 2026 Annual Meeting of Stockholders may incentivize the director to work towards the company's long-term success.

Next Steps

• Monitor future Form 4 filings to track changes in insider ownership.
• Observe the company's performance leading up to the 2026 Annual Meeting of Stockholders, as the vesting and exercisability of the securities are linked to this event.

Key Dates